The Relationship of Biochemical Markers of Bone Turnover to Bone Density Changes in Postmenopausal Women: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
We assessed the associations of eight bone turnover markers (BTMs) with baseline and 1‐year percentage changes in lumbar spine and hip bone mineral density (BMD) of 293 postmenopausal women undergoing treatment with hormone replacement therapy (HRT) or placebo using squared correlation coefficients...
Gespeichert in:
Veröffentlicht in: | Journal of bone and mineral research 1999-09, Vol.14 (9), p.1583-1595 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We assessed the associations of eight bone turnover markers (BTMs) with baseline and 1‐year percentage changes in lumbar spine and hip bone mineral density (BMD) of 293 postmenopausal women undergoing treatment with hormone replacement therapy (HRT) or placebo using squared correlation coefficients (R2). In 239 women assigned to treatment with estrogen alone or with with estrogen plus progestins (active treatment), mean percentage changes for all markers decreased significantly and remained below baseline values through 3 years of study, whereas mean percentage changes for 54 women assigned to the placebo group showed no significant change from baseline in any marker. At baseline, age and body mass index (BMI) together accounted for 16% and 25% of the variance in spine and hip BMD, respectively. The telopeptide resorption marker, cross‐linked N‐telopeptide of type I collagen (NTX), alone accounted for 12% and 8% of variance, respectively. Another telopeptide, carboxy‐terminal telopeptide of type I collagen (Crosslaps), accounted for 8% and 7% of variance, respectively. A bone‐specific alkaline phosphatase (BALP‐2) accounted for 8% of variance at the spine and 5% at the hip. No other marker accounted for more than 5% of total variance at either site; adding either baseline NTX, Crosslaps, or BAP‐2 to regressions containing age and BMI increased R2 values at the spine and hip to about 22% and 28%, respectively. In the placebo group, baseline spine BMD accounted for 4% of the variance in 1‐year spine BMD percentage change, whereas baseline values for age and BMI accounted for 1% and 0% of the variance, respectively; none of the three accounted for more than 0% of hip BMD percentage change; Crosslaps and NTX contributed 5% and 4% to the variance in 1‐year spine BMD percentage change, but other markers accounted for < 2% of variance at the spine. At the hip, another BALP (BALP‐1) accounted for 4% of variance, but no other baseline marker except NTX accounted for more than 1% of variance. In the active treatment group, baseline values for age, BMI, and spine BMD together accounted for 13% of the percentage change in spine BMD and for 4% of the BMD change at the hip. No individual or pair of baseline markers significantly enhanced these R2 values, but addition of 1‐year percentage changes in some individual markers did significantly increase it. The largest R2 value was obtained by adding the percentage change in BALP‐2, which increased the R2 in spine BMD percen |
---|---|
ISSN: | 0884-0431 1523-4681 |
DOI: | 10.1359/jbmr.1999.14.9.1583 |